𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Oral piritrexim — A phase II study in patients with advanced soft tissue sarcoma

✍ Scribed by Judith D. Schiesel; Matthew Carabasi; Gordon Magill; Ephraim Casper; Edgar Cheng; Linda Marks; Jan Feyzi; Neil J. Clendeninn; Richard V. Smalley

Publisher
Springer US
Year
1992
Tongue
English
Weight
129 KB
Volume
10
Category
Article
ISSN
0167-6997

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Results of a 2-arm Phase II study of 9-n
Results of a 2-arm Phase II study of 9-nitrocamptothecin in patients with advanced soft-tissue sarcomas
✍ Shreyaskumar R. Patel; Jennifer Beach; Nicholas Papadopoulos; M. Andrew Burgess; 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 English ⚖ 110 KB 👁 3 views

## Abstract ## BACKGROUND The authors conducted a 2‐arm Phase II trial of 9‐nitrocamptothecin (9‐NC), an oral topoisomerase I inhibitor, to define response rates in patients with gastrointestinal (GI) leiomyosarcomas and other soft‐tissue sarcomas (STS). ## METHODS Patients were required to prov

Phase II trial of cisplatin (CPDD) in pr
Phase II trial of cisplatin (CPDD) in previously treated patients with advanced soft tissue sarcoma
✍ Joseph Brenner; Gordon B. Magill; Peter P. Sordillo; Edgar W. Cheng; Allan Yagod 📂 Article 📅 1982 🏛 John Wiley and Sons 🌐 English ⚖ 249 KB 👁 3 views

Thirty-six previously treated adult patients with advanced soft tissue sarcomas received CPDD 120 mg/m2 with mannitol diuresis. There were only two (6%) partial responses and five (15%) minor responses in 34 evaluable patients. Toxicity included nausea and vomiting, myelosuppression, mild ototoxicit